Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...

Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...

Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...

Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official [claimed the shots]( ...

Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Get the latest on Novavax stock (NVAX) after breaking its losing streak. Discover updated profitability targets and analyst ratings.

Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure ...

‘Chief Medical Officer’s Annual Report 2025: Infections’ was published at 15:00 UK time on Thursday the 4th of December 2025. Prof Andrew Morris: Andrew is the President of the Academy of Medical ...

US FDA's vaccine director Dr. Vinay Prasad wrote a memo to their staff that claimed multiple child deaths were related to ...

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Shares of Novavax Inc. NVAX slipped 3.23% to $7.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.68% to ...